|
|
Blood, 15 April 2005, Vol. 105, No. 8, pp. 3206-3213.
Prepublished online as a Blood First Edition Paper on December 23, 2004; DOI 10.1182/blood-2004-10-3944.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand
Jens Dannull,
Smita Nair,
Zhen Su,
David Boczkowski,
Christian DeBeck,
Benjamin Yang,
Eli Gilboa, and
Johannes Vieweg
From the Genitourinary Cancer Immunotherapy Program, Division of Urology, Duke University Medical Center; and the Department of Surgery, Duke University Medical Center, Durham, NC.
The objective of this study was to investigate whether the immunostimulatory properties of human monocyte-derived dendritic cells (DCs) could be enhanced by triggering OX40/OX40L signaling. Since monocyte-derived DCs possess only low-cell surface levels of OX40L in the absence of CD40 signaling, OX40L was expressed by transfection of DCs with the corresponding mRNA. We show that OX40L mRNA transfection effectively enhanced the immunostimulatory function of DCs at multiple levels: OX40L mRNA transfection augmented allogeneic and HLA class II epitope-specific CD4+ T-cell responses, improved the stimulation of antigen-specific cytotoxic T lymphocytes (CTLs) in vitro without interfering with the prostaglandin E2 (PGE2)–mediated migratory function of the DCs, and facilitated interleukin 12 p70 (IL-12p70)–independent T helper type 1 (Th1) polarization of naive CD4+ T-helper cells. Furthermore, vaccination of tumor-bearing mice using OX40L mRNA–cotransfected DCs resulted in significant enhancement of therapeutic antitumor immunity due to in vivo priming of Th1-type T-cell responses. Our data suggest that transfection of DCs with OX40L mRNA may represent a promising strategy that could be applied in clinical immunotherapy protocols, while circumventing the current unavailability of reagents facilitating OX40 ligation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. Keller, Y. Xiao, V. Peperzak, S. H. Naik, and J. Borst
Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
Blood,
May 21, 2009;
113(21):
5167 - 5175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med.,
May 11, 2009;
206(5):
1103 - 1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Fujii, A. Goto, and K. Shimizu
Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity
Blood,
April 30, 2009;
113(18):
4262 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Krause, M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler
Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells
Blood,
March 12, 2009;
113(11):
2451 - 2460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Burrell, G. Lu, X. C. Li, and D. K. Bishop
OX40 Costimulation Prevents Allograft Acceptance Induced by CD40-CD40L Blockade
J. Immunol.,
January 1, 2009;
182(1):
379 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Minkis, D. G. Kavanagh, G. Alter, D. Bogunovic, D. O'Neill, S. Adams, A. Pavlick, B. D. Walker, M. A. Brockman, R. T. Gandhi, et al.
Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA-Transfected Dendritic Cells
Cancer Res.,
November 15, 2008;
68(22):
9441 - 9450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Melhem, S. M. Gleason, X. D. Liu, and S. M. Barratt-Boyes
High-Level Antigen Expression and Sustained Antigen Presentation in Dendritic Cells Nucleofected with Wild-Type Viral mRNA but Not DNA
Clin. Vaccine Immunol.,
September 1, 2008;
15(9):
1337 - 1344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mariotti, V. Sargentini, C. Marcantonio, E. Todero, R. Teloni, M. C. Gagliardi, A. R. Ciccaglione, and R. Nisini
T-cell-mediated and antigen-dependent differentiation of human monocyte into different dendritic cell subsets: a feedback control of Th1/Th2 responses
FASEB J,
September 1, 2008;
22(9):
3370 - 3379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Redmond, M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg
Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist
J. Immunol.,
December 1, 2007;
179(11):
7244 - 7253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tuyaerts, S. Van Meirvenne, A. Bonehill, C. Heirman, J. Corthals, H. Waldmann, K. Breckpot, K. Thielemans, and J. L. Aerts
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells
J. Leukoc. Biol.,
July 1, 2007;
82(1):
93 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Murata, B. H. Ladle, P. S. Kim, E. R. Lutz, M. E. Wolpoe, S. E. Ivie, H. M. Smith, T. D. Armstrong, L. A. Emens, E. M. Jaffee, et al.
OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen
J. Immunol.,
January 15, 2006;
176(2):
974 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Serghides, J. Bukczynski, T. Wen, C. Wang, J.-P. Routy, M.-R. Boulassel, R.-P. Sekaly, M. Ostrowski, N. F. Bernard, and T. H. Watts
Evaluation of OX40 Ligand as a Costimulator of Human Antiviral Memory CD8 T Cell Responses: Comparison with B7.1 and 4-1BBL
J. Immunol.,
November 15, 2005;
175(10):
6368 - 6377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
